Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies.

Abstract

In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.

• Authors: Rodrigo Cartin-Ceba, Michael Halank, Hossein-Ardeschir Ghofrani, Marc Humbert, John Mattson, Arno Fritsch, Michael Krowka
• Journal: Pulmonary circulation (Pulm Circ) 2018 Apr-Jun Vol. 8 Issue 2 Pg. 2045894018769305 ISSN: 2045-8932 [Print] United States
• PMID: 29565224 (Publication Type: Journal Article)